The first biosimilar product was approved this spring. Pharmacists will want to familiarize themselves with this new class of therapies. Below are the five top things that a pharmacist should know about biosimilars.
While biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.
Canada, the E.U., South Korea, Japan, India, and Australia — all have had clear regulatory pathways in place for years. The United States has been working on a biosimilars pathway for almost a decade. What's different?